“Non-Cystic Fibrosis Bronchiectasis Pipeline” has been added to DelveInsight
Non-Cystic Fibrosis Bronchiectasis Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competitors, launch date along with product development activities.
Download free sample copy here- https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight
Non-Cystic Fibrosis Bronchiectasis Overview
Non‐cystic fibrosis bronchiectasis (NCFB) is a chronic, progressive respiratory disorder characterized by irreversibly and abnormally dilated airways, persistent cough, excessive sputum production, and recurrent pulmonary infections. Non‐cystic fibrosis bronchiectasis often coexists with other respiratory conditions, such as chronic obstructive pulmonary disease.
Non-Cystic Fibrosis Bronchiectasis Symptoms
Symptoms include chronic (lasting more than four weeks) wet or productive cough, shortness of breath, abnormal chest sounds, weakness, weight loss and fatigue. Recurrent chest infections may produce coloured mucus. A chronic wet cough is often the only symptom present for some children with bronchiectasis.
Non-Cystic Fibrosis Bronchiectasis Diagnosis
Bronchiectasis is diagnosed via a chest computed tomography (CT) scan. A chest X-ray, bronchoscopy, lung function, blood tests, sputum culture, and other tests (e.g. immune function, sweat test and genetics) for associated diseases may also be performed.
Non-Cystic Fibrosis Bronchiectasis Treatment
Non-Cystic Fibrosis Bronchiectasis Emerging Drug
HF 6333 is a medicinal product on development for the treatment of cystic fibrosis and non-CF bronchiectasis and undergoing clinical testing. It has not yet been approved by the authorities for the treatment of these diseases. CHF6333 is an inhaled anti-inflammatory which mechanism of action is based on the inhibition of Human Neutrofil Elastase.
Non-Cystic Fibrosis Bronchiectasis Key Players
Non-Cystic Fibrosis Bronchiectasis Emerging Drugs Analysis
The dynamics of Non‐Cystic Fibrosis Bronchiectasis market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, and incremental healthcare spending across the world. Key players in the therapeutic market of Non‐Cystic Fibrosis Bronchiectasis at the global level are Zambon, Novartis, Insmed, Aradigm Corporation and others. Expected launch of these emerging therapies Colistimethate sodium (Zambon), INS1007 (Insmed), Ciprofloxacin dispersion for inhalation (Aradigm Corporation), and others will significantly impact the Non‐Cystic Fibrosis Bronchiectasis market during the forecast period (2021–2030).
Non-Cystic Fibrosis Bronchiectasis Report Highlights
Following is the TOC of Non-cystic Fibrosis Bronchiectasis Pipeline Report
What are the key questions answered?
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: www.delveinsight.com/